Jacobio Pharmaceuticals Group Résultats passés
Passé contrôle des critères 0/6
Jacobio Pharmaceuticals Group has been growing earnings at an average annual rate of 28.7%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been declining at an average rate of 79.9% per year.
Informations clés
28.7%
Taux de croissance des bénéfices
53.7%
Taux de croissance du BPA
Biotechs Croissance de l'industrie | 11.0% |
Taux de croissance des recettes | -79.9% |
Rendement des fonds propres | -39.9% |
Marge nette | -1,560.9% |
Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
Most Shareholders Will Probably Agree With Jacobio Pharmaceuticals Group Co., Ltd.'s (HKG:1167) CEO Compensation
May 31Is Jacobio Pharmaceuticals Group (HKG:1167) Using Debt Sensibly?
May 29We're Hopeful That Jacobio Pharmaceuticals Group (HKG:1167) Will Use Its Cash Wisely
May 10Time To Worry? Analysts Are Downgrading Their Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Outlook
Aug 26We're Not Very Worried About Jacobio Pharmaceuticals Group's (HKG:1167) Cash Burn Rate
Jul 29We Think Jacobio Pharmaceuticals Group (HKG:1167) Can Afford To Drive Business Growth
Apr 29What Percentage Of Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Shares Do Insiders Own?
Mar 21Ventilation des recettes et des dépenses
Comment Jacobio Pharmaceuticals Group gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
30 Jun 24 | 23 | -362 | 44 | 350 |
31 Mar 24 | 43 | -361 | 45 | 361 |
31 Dec 23 | 64 | -359 | 47 | 372 |
30 Sep 23 | 72 | -385 | 45 | 420 |
30 Jun 23 | 81 | -410 | 43 | 468 |
31 Mar 23 | 89 | -391 | 43 | 457 |
31 Dec 22 | 96 | -372 | 43 | 446 |
30 Sep 22 | 123 | -332 | 46 | 391 |
30 Jun 22 | 150 | -292 | 49 | 336 |
31 Mar 22 | 151 | -297 | 47 | 308 |
31 Dec 21 | 153 | -301 | 45 | 281 |
30 Sep 21 | 348 | -570 | 52 | 259 |
30 Jun 21 | 544 | -839 | 60 | 237 |
31 Mar 21 | 515 | -1,177 | 57 | 211 |
31 Dec 20 | 486 | -1,514 | 54 | 186 |
30 Sep 20 | 243 | -1,298 | 65 | 171 |
30 Jun 20 | 0 | -1,082 | 77 | 156 |
31 Mar 20 | 0 | -753 | 74 | 147 |
31 Dec 19 | 0 | -425 | 71 | 139 |
Des revenus de qualité: 1167 is currently unprofitable.
Augmentation de la marge bénéficiaire: 1167 is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 1167 is unprofitable, but has reduced losses over the past 5 years at a rate of 28.7% per year.
Accélération de la croissance: Unable to compare 1167's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: 1167 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.5%).
Rendement des fonds propres
ROE élevé: 1167 has a negative Return on Equity (-39.92%), as it is currently unprofitable.